interpath-001: v940, a neoantigen therapy, with pembrolizumab in melanoma
Published 1 month ago • 46 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
1:22
interpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
-
1:21
interpath-002: pembrolizumab with a neoantigen therapy in completely resected nsclc
-
4:10
a personalized mrna vaccine with pembrolizumab in melanoma
-
3:10
mrna-4157, a novel mrna vaccine, with pembrolizumab in melanoma
-
4:22
neoantigen vaccine with pembrolizumab has clear benefit in resected melanoma
-
0:39
pembrolizumab, emavusterib radiosurgery: a novel trimodal therapy for metastatic melanoma
-
1:30
individualized antigen therapy in melanoma
-
4:04
neoantigens for melanoma treatment
-
1:20
comparing petosemtamab and pembrolizumab in hnscc with existing therapies
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
1:20
neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
1:12
investigators present updated results of the opacin trial for melanoma
-
1:29
cmp-001 for melanoma and hnscc
-
2:34
keynote-029: pembrolizumab with ipilimumab for melanoma
-
1:27
analyzing the role of checkpoint inhibitors for the treatment of melanoma
-
2:33
what is keytruda?
-
1:57
advanced melanoma trial when keytruda alone is not enough